Andecaliximab

Phase 2Monoclonal antibody

Andecaliximab is one of 226 biologic programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

225

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Fibrodysplasia Ossificans ProgressivaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Cystic FibrosisActive, not recruiting

Spinal Cord InjuryActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 1

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 1

Active, not recruiting

Fibrodysplasia Ossificans ProgressivaPhase 2/Phase 3

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Ulcerative ColitisPhase 1

Active, not recruiting

Cystic FibrosisPhase 2

Active, not recruiting

Spinal Cord InjuryPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Actemra

Cimzia

30 5

Simponi

Johnson & Johnson

Preclinical

19 6

Andecaliximab

Gilead

Phase 2

1 7

Enbrel

IImmunex

Preclinical

64 8

Remicade

OOrganon and Co

Preclinical

43 9

Arcoxia

Novartis

Preclinical

4 10

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2/3Active, not recruiting

Fibrodysplasia Ossificans Progressiva

NCT06508021

Clinical

Trials by Indication[1]

Gastroesophageal Junction Adenocarcinoma3 trials

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Terminated· Gilead logo

Gilead·Phase 1·NCT02862535·36 enrolled

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Completed· Gilead logo

Gilead·Phase 3·NCT02545504·432 enrolled

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Completed· Gilead logo

Gilead·Phase 2·NCT02864381·144 enrolled

Ulcerative Colitis2 trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Completed· Gilead logo

Gilead·Phase 1·NCT01831427·74 enrolled

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

Terminated· Gilead logo

Gilead·Phase 2/3·NCT02520284·165 enrolled

Spinal Cord Injury1 trial

A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

Recruiting·AAshibio Inc·Phase 1/2·NCT07024407·10 enrolled

Rheumatoid Arthritis1 trial

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Terminated· Gilead logo

Gilead·Phase 2·NCT02862574·15 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

Terminated· Gilead logo

Gilead·Phase 2·NCT02405442·187 enrolled

4 more indications

Chronic Obstructive Pulmonary Disease1 trial

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Completed· Gilead logo

Gilead·Phase 1·NCT02077465·11 enrolled

Fibrodysplasia Ossificans Progressiva1 trial

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Active, not recruiting·AAshibio Inc·Phase 2/3·NCT06508021·92 enrolled

Advanced Solid Tumors1 trial

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Completed· Gilead logo

Gilead·Phase 1·NCT01803282·236 enrolled

Cystic Fibrosis1 trial

Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

Terminated· Gilead logo

Gilead·Phase 2·NCT02759562·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Andecaliximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Andecaliximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Andecaliximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Gilead

Andecaliximab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Gastroesophageal Junction Adenocarcinoma3 trials

Ulcerative Colitis2 trials

Spinal Cord Injury1 trial

Rheumatoid Arthritis1 trial

Safety and Efficacy1 trial

Chronic Obstructive Pulmonary Disease1 trial

Fibrodysplasia Ossificans Progressiva1 trial

Advanced Solid Tumors1 trial

Cystic Fibrosis1 trial

References

Drug Info

Quick Facts

Related News